Skip to content
Menu

Krystal Biotech, Inc. KRYS

Full chart Compare
Set alert

Price alert · KRYS

All alert types
314.83 USD -0.99 (-0.31%)

As ofNov 20, 2026, 1:20 PM EST

312.38 Day range 315.75
204.23 52-week range 378.15
YTD
+27.70%
1 year
+54.16%

Fundamental scorecard

14 of 25 checks passed on KRYS’s reported financials

ValueGrowthProfitabilityHealthDividend

14of 25 checks passed

  • Value 1 of 5
  • Growth 4 of 5
  • Profitability 4 of 5
  • Financial health 5 of 5
  • Dividend 0 of 5

Statements to Sep 30, 2026.

Value 1 of 5

  • Passed:P/E below its own 5-year median P/E 41.5 against a 5-year median of 50.5.
  • Failed:P/E under 20 P/E 41.5: an earnings yield of 2.4%.
  • Failed:Price to sales below its own 5-year median Price to sales 19.9 against a 5-year median of 18.4.
  • Failed:Price to book below its own 5-year median Price to book 6.5 against a 5-year median of 4.5.
  • Failed:Free cash flow yield above 4% Free cash flow of 310M is 3.3% of the market value.

Growth 4 of 5

  • Passed:Revenue grew over the last year Revenue of 470M is +26.0% on the 12 months before.
  • No data:Revenue grew more than 5% a year over five years Not enough data to decide.
  • Passed:Earnings per share grew over the last year EPS 7.37 against 6.68 in the 12 months before.
  • Passed:Earnings per share grew more than 5% a year over five years EPS -1.71 in FY 2020, 6.84 in FY 2025.
  • Passed:Analysts expect higher earnings per share over the next year The average forward estimate is +25.4% on the last 12 months.

Profitability 4 of 5

  • Passed:Profitable over the last year Net income of 225M over the last 12 months.
  • Failed:Profitable in each of the last five fiscal years A profit in 3 of the last 5 fiscal years.
  • Passed:Return on equity above 15% Return on equity of 17.5%.
  • Passed:Net margin above its 5-year average Net margin of 47.9% against a 5-year average of 35.0%.
  • Passed:Free cash flow is at least 80% of net income Free cash flow of 310M is 137.7% of net income.

Financial health 5 of 5

  • Passed:Short-term assets cover short-term liabilities Short-term assets of 1.12B against short-term liabilities of 142M.
  • Passed:Short-term assets cover long-term liabilities Short-term assets of 1.12B against long-term liabilities of 8.33M.
  • Passed:Net debt under 40% of equity More cash than debt: 912M of cash against 8.59M of debt.
  • Passed:Operating cash flow covers at least 20% of debt Operating cash flow of 324M is 3771.9% of debt.
  • Passed:Operating profit covers interest at least 3 times No interest expense reported.

Dividend 0 of 5

  • Failed:Pays a dividend No dividend paid.
  • Failed:Yield above 1.5% No dividend paid.
  • Failed:Pays out under 75% of profit No dividend paid.
  • Failed:Covered by free cash flow No dividend paid.
  • Failed:Not cut in the last five fiscal years No dividend paid.

Mechanical checks on reported financials against fixed thresholds. They describe the numbers; they are not a recommendation to buy or sell.

Included in Essentials and up

Sign in to see Fair value

Discounted cash flow estimates against the price, and the P/E against its industry and sector.

Included in Essentials and up

Sign in to see Head count and owner earnings

Employees by annual report and the cash the business earns for its owners.

Included in Essentials and up

Sign in to see P/E against peers

The price to earnings ratio beside the closest competitors and their median.

Financial position

What KRYS owns and owes, as of Sep 30, 2026

Short term and long term

Balance sheet · 1.59B of assets

Debt, equity and cash by year

Now: 903M more cash than debt

Fiscal years, then the newest quarter. Cash includes short-term investments.

From the company’s SEC filings.

Included in Essentials and up

Sign in to see Cash flow and returns

How profit turns into free cash flow, and the returns on equity, assets and capital.

Financial health

Altman Z-Score

39.04 Safe zone

Bankruptcy-risk model: below 1.81 distress, above 2.99 safe.

Piotroski F-Score

4 / 9 Average

Nine pass/fail tests of profitability, leverage and efficiency.

Rating

B+3 / 5 overall

  • DCF 4
  • Return on Equity 4
  • Return on Assets 5
  • Debt / Equity 4
  • P/E 1
  • P/B 1

Valuation

P/E 34.8×
P/S 18.3×
P/B 5.9×
P/FCF 37.8×
EV/EBITDA 33.9×
EV/Sales 17.1×
FCF Yield 2.6%

Profitability

Gross Margin 92.6%
Operating Margin 41.5%
Net Margin 52.6%
ROE 16.8%
ROIC 13.1%
ROA 15.4%

Growth (YoY)

Revenue 33.9%
Operating Income 145.5%
EPS (diluted) 128.0%
Free Cash Flow 58.5%

Financial Health

Current Ratio 10.0×
Quick Ratio 9.6×
Debt / Equity 0.0×
Net Debt / EBITDA -2.5×
Interest Coverage 0.0×

Dividends

Dividend Yield 0.0%
Payout Ratio 0.0%

Annual · latest fiscal year ends 2025-12-31